LAKE FOREST, Ill. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, today announced that members of senior management will participate at the 16 th Annual Morgan Stanley Global Healthcare

Purdue to pay Assertio $62 million in two installments LAKE FOREST, Ill. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the Company has entered into a settlement agreement with Purdue Pharma L.P. with regard to the Company’s patent infringement

Name Change Reflects Company’s Focus on Neurology, Orphan and Specialty Businesses LAKE FOREST, Ill. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name

-- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End -- -- Announces Agreement with PDL BioPharma to Monetize Royalty Stream;

LAKE FOREST, Ill. , July 09, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018 , before the open of markets. Following the announcement, the Company will host a conference call beginning at

LAKE FOREST, Ill. , July 06, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) announced that effective July 3, 2018 , the Company granted ten newly-hired employees a total of 512,439 restricted stock units (“RSUs”).  The RSUs were granted as inducements material to each such individual’s entry

LAKE FOREST, Ill. , June 07, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) announced that the Company will grant Phillip B. Donenberg , the Company’s new Chief Financial Officer and Senior Vice President, 87,163 restricted stock units (“RSUs”) and 87,163 target performance stock units

LAKE FOREST, Ill. , June 05, 2018 (GLOBE NEWSWIRE) -- Lake Forest, Illinois , June 5, 2018 - Depomed, Inc. (NASDAQ:DEPO) today announced that it has appointed Phillip B. Donenberg as Chief Financial Officer and Senior Vice President, effective July 16, 2018. Mr. Donenberg will succeed August J.

- Company Confirms Previous 2018 Guidance for Neurology Franchise Net Sales and Non-GAAP Adjusted EBITDA - - Amends Existing Agreement for CAMBIA Line Extension – - Announces New Co-Promotion Agreement for Zipsor – - Begins Enrollment in New Clinical Trial Using Cosyntropin to Treat Rare Pediatric

LAKE FOREST, Ill. , May 07, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference in a session scheduled for 1:30 pm ET on Tuesday, May 22, 2018 in New York, NY .